Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
Renessen was a biotechnology joint venture established in 1999 as a 50/50 partnership between Monsanto and Cargill. The company focused on developing and commercializing genetically modified crops with enhanced nutritional profiles for the global animal feed market. Its flagship product, Mavera high-lysine corn, was designed to reduce the need for synthetic lysine supplements in poultry and swine diets. By combining Monsanto's seed technology with Cargill's grain processing and marketing capabilities, Renessen aimed to capture value across the entire agricultural supply chain. The venture was eventually dissolved in 2010 after facing regulatory hurdles and shifting strategic priorities within its parent companies.
Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on Renessen.